Drug Trial Radar · NCT03386513
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Jan 2, 2018
Primary completion
Oct 2, 2024
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Myeloproliferative Neoplasm
Interventions
IMGN632Drug
CD123-targeted ADC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) ParticipantsTime frame: Up to approximately 81 months
Locations
18 sites in 4 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center /ID# 275372
Birmingham, Alabama
Banner Md Anderson Cancer Center /ID# 269294
Gilbert, Arizona
City of Hope National Medical Center /ID# 269293
Duarte, California
UCLA - University of California Los Angeles Medical Center /ID# 269066
Los Angeles, California
Moffitt Cancer Center /ID# 269291
Tampa, Florida
Dana-Farber Cancer Institute /ID# 269290
Boston, Massachusetts
Roswell Park Cancer Institute /ID# 269289
Buffalo, New York
Duplicate_Duke University Health System /ID# 275370
Durham, North Carolina
Baylor University Medical Ctr. /ID# 275371
Dallas, Texas
MD Anderson Houston /ID# 269288
Houston, Texas
Fred Hutchinson Cancer Center - Seattle - Fairview Avenue North /ID# 269292
Seattle, Washington
Hopital Saint Antoine /ID# 269298
Paris, France
Institut Paoli-Calmettes /ID# 269299
Marseille, Bouches-du-Rhone, France
Duplicate_CHU de Besancon - Jean Minjoz /ID# 275369
Besançon, Doubs, France
CHU Amiens-Picardie Site Sud /ID# 269068
Amiens, Somme, France
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 269297
Meldola, Forlì-Cesena, Italy
Istituto Europeo Di Oncologia /ID# 269296
Milan, Milano, Italy
Hospital Universitario y Politecnico La Fe /ID# 269295
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.